Efficacy and safety of a modified intravenous recombinant tissue plasminogen activator regimen in chinese patients with acute ischemic stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 22, Issue 5, 2013, Pages 690-693

  Pan, Shu Ming ^a   Liu, Jia Fu ^a   Liu, Ming ^a   Shen, Sa ^a   Li, Hao Jun ^a   Dai, Li Hua ^a   Chen, Xiang Jun ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Acute ischemic stroke; Chinese; recombinant tissue plasminogen activator; thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHINESE; DEMOGRAPHY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PRIORITY JOURNAL; RANKIN SCALE; RISK FACTOR; VASCULAR DISEASE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CHI-SQUARE DISTRIBUTION; CHINA; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84879735767     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2012.08.018     Document Type: Article

References (15)

1. T. Truelsen, M. Ekman, and G. Boysen Cost of stroke in Europe Eur J Neurol 12 Suppl 1 2005 78 84
2. M. Liu, B. Wu, and W.Z. Wang Stroke in China: Epidemiology, prevention, and management strategies Lancet Neurol 6 2007 456 464
3. V.L. Feigin, C.M. Lawes, and D.A. Bennett Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review Lancet Neurol 8 2009 355 369
4. X.H. Fang, C.X. Wang, and L.P. Mei Progress in epidemiology study on stroke Chin J Epidemiol 32 2011 847 853
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
6. W. Hacke, M. Kaste, and E. Bluhmki Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
7. J. Nakagawara, K. Minematsu, and Y. Okada Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-marketing alteplase registration study (J-MARS) Stroke 41 2010 1984 1989
8. A.M. Ross, R. Gao, and K.S. Coyne A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial Am Heart J 142 2001 244 247
9. C. Wang, Z.G. Zhai, and Y.H. Yang Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: A randomized, multicenter, controlled trial Chest 137 2010 254 262
10. J. Kwan, P. Hand, and P. Sandercock Improving the efficiency of delivery of thrombolysis for acute stroke: A systematic review Q J Med 97 2000 273 279
11. C.E. Szoeke, M.W. Parsons, and K.S. Butcher Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital Med J Aust 178 2003 324 328
12. J.H. Kahn, J. Viereck, and C. Kase The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke J Emerg Med 29 2005 273 277
13. J.J. Batmanian, M. Lam, and C. Matthews A protocol driven model for the rapid initiation of stroke thrombolysis in the emergency department (ED) Intern Med J 36 2006 A1 A14
14. S.R. Messé, S.E. Kasner, and B.L. Cucchiara Dosing errors did not have a major impact on outcome in the NINDS t-PA stroke study J Stroke Cerebrovasc Dis 20 2011 236 240
15. N. Wahlgren, N. Ahmed, and A. Davalos Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study Lancet 369 2007 275 282